The LIMCR (Laboratory for Immunological and Molecular Cancer Research), which is integrated in the Third Medical Department of the Paracelsus Medical University Hospital, opened its doors in 2005 and has its research focus on chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS) and acut myeloid leukemia (AML). The LIMCR maintains a close connection with the clinic to ensure maximum synergy and efficacy in cancer therapy.


Click here to read more

Research Groups

 Murine-Lymphoma Models

Group leader: PD Dr. Alexander Egle

“The complexity of the disease can be mimicked in the murine model. In this system we are analyzing the effect of novel therapy concepts and the communication of leukemic cells with the immune system.” More

 Tumor immunology

Group leader: Dr. Roland Geisberger

“Leukemic cells benefit from deactivating other immune cells. We study the underlying mechanisms and search for ways to reactivate the immune system to combat leukemia.” More


Group leader: Assoc. Prof. Dr. Tanja Hartmann

"Leukemia cells are strongly dependent on the lymphoid tumor microenvironment, where they receive proliferative and pro-survival signals. We are interested in how CLL cells localize adjacent to these supportive signals." More


Presseartikel November 2018

"Den Krebs ausgetrickst"

Prim. Univ.Prof. Dr. Richard Greil, UK für Innere Medizin III der PMU

Salzburger Nachrichten


3. Salzburg Breast Cancer Talk

Preliminary Program

01.-02. März 2019


Univ.Prof. Dr. Richard Greil, OA Dr. Simon Gampenrieder, OA Dr. Gabriel Rinnerthaler

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in cooperation with the Cancer Cluster Salzburg and AGMT gemeinnützige GmbH


Presseartikel October 2018

Alle Onko News AUSTRIA Ausgaben online unter: